If you have been reading about synthetic peptide and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-04-03. Where a claim depends on a specific study, the study is described rather than over-claimed.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
| Property | Value | Notes |
|---|---|---|
| Primary research area | Obesity and metabolic regulation | Studied in cell, animal, and human models |
| Highest reported trial phase | Phase II | Public summaries describe mixed results |
| Common route in trials | Subcutaneous injection | Typical for peptide therapeutics |
| Regulatory example | 2013 Australian anti-doping review | Classification was debated at the time |
| Approval status | Not approved as a human medicine | Status can change by jurisdiction |
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
== Use and effects == In his book PiHKAL (Phenethylamines I Have Known and Loved), Alexander Shulgin lists MDDMA's dose as greater than 150 mg orally and its duration as unknown. Findings on the effects of MDDMA are very mixed. In two reports, with 150 mg and 1,000 mg both orally, no effects whatsoever occurred. In another report, 550 mg orally resulted in very negative effects. Finally, two people who used 200 mg orally found that it produced very pleasant effects for 20 minutes, wore off, but then resurged to produce even stronger effects 4 hours later. The higher-dose reports were communicated to Shulgin anonymously and he was uncertain whether the actual substance employed was indeed MDDMA. More research seems necessary to characterize MDDMA, but Shulgin expected that a "pretty hefty dose" would be required for it to produce effects.
This technique is often used for research in e.g. elite sports training, ergonomics, rehabilitation, patient monitoring, neonatal research, functional brain monitoring, brain–computer interface, urology (bladder contraction), neurology (Neurovascular coupling) and more. Hemoglobin mass can be measured in humans using the non-radioactive, carbon monoxide (CO) rebreathing technique that has been used for more than 100 years. With this technique, a small volume of pure CO gas is inhaled and rebreathed for a few minutes. During rebreathing, CO binds to hemoglobin present in red blood cells. Based on the increase in blood CO after the rebreathing period, the hemoglobin mass can be determined through the dilution principle. Long-term control of blood sugar concentration can be measured by the concentration of Hb A1c. Measuring it directly would require many samples because blood sugar levels vary widely through the day. Hb A1c is the product of the irreversible reaction of hemoglobin A with glucose. A higher glucose concentration results in more Hb A1c. Because the reaction is slow, the Hb A1c proportion represents glucose level in blood averaged over the half-life of red blood cells, is typically about 120 days. An Hb A1c proportion of 6.0% or less show good long-term glucose control, while values above 7.0% are elevated. This test is especially useful for diabetics. The functional magnetic resonance imaging (fMRI) machine uses the signal from deoxyhemoglobin, which is sensitive to magnetic fields since it is paramagnetic.
== Prognosis == The use of DMARDs in the management of JIA have made disease-free remission achievable for the majority of children with JIA. Clinical remission can be defined as the absence of signs and symptoms of inflammatory disease activity, including extra-articular manifestations of the disease. Differentiating subtypes of JIA helps to target treatment and leads to more positive outcomes, however subtype is not the only predictor of JIA outcome. Poor prognostic factors include arthritis of the hip, cervical spine, ankles or wrists; prolonged elevation of inflammatory markers; and radiographic evidence of joint damage including erosions or joint space narrowing. Patients with RF-positive polyarthritis often have worse outcomes associated with more aggressive disease. Despite this, the probability of this subgroup achieving inactive disease at least once within five years was shown to be 90% in a large Canadian study. Research is currently being undertaken into clinical prediction models to allow earlier identification of children who are likely to have a worse prognosis. Compliance with therapy, especially medications, has a positive correlation with disease outcome. Disease recurrence after medical therapy discontinuation is high, with 30-100% of children having clinical relapse of disease after treatment discontinuation. It has been previously suggested that children with JIA are at an increased risk of malignancies when being treated with anti-TNF therapy.
Chocolate milk is a type of flavoured milk made by mixing cocoa powder with milk (either dairy or plant-based). It is a food pairing in which the milk's mouthfeel masks the dietary fibres of the (non-fat) cocoa solids of cocoa powder.
Sources: en.wikipedia.org
A conjugated protein is a protein that functions in interaction with other (non-polypeptide) chemical groups attached by covalent bonding or weak interactions. These non-Protein components are essential for the proteins biological activity and are not made up of amino acids. Many proteins contain only amino acids and no other chemical groups, and they are called simple proteins. However, other kind of proteins yield, on hydrolysis, some other chemical component in addition to amino acids and they are called conjugated proteins. The non-amino part of a conjugated protein is usually called its prosthetic group, and it plays a crucial role in determining the protein's structure and function. Most prosthetic groups are formed from vitamins, however, they can vary widely in composition and may include molecules like carbohydrates, lipids, metal ion, or nucleic acids. Conjugated proteins are classified on the basis of the chemical nature of their prosthetic groups. This classification reflects the differences of their functions, which includes roles in transport, enzymatic activity, structural support, and cellular communication. Conjugated proteins are essential to many biological processes because of their combined protein and non-protein components.
== Biological function == Physiologically SPP processes signal peptides of classical MHC class I preproteins. A nine amino acid-long cleavage fragment is then presented on HLA-E receptors and modulates the activity of natural killer cells. SPP also plays a pathophysiological role; it cleaves the structural nucleocapsid protein (also known as core protein) of the Hepatitis C virus and thus influences viral reproduction rate. In mice, a nonamer peptide originating from the SPP protein serves as minor histocompatibility antigen HM13 that plays a role in transplant rejection The homologous proteases SPPL2A and SPPL2B promote the intramembrane cleavage of TNFα in activated dendritic cells and might play an immunomodulatory role. For SPPL2c and SPPL3 no substrates are known. SPPs do not require cofactors as demonstrated by expression in bacteria and purification of a proteolytically active form. The C-terminal region defines the functional domain, which is in itself sufficient for proteolytic activity.
Pirepemat (INNTooltip International Nonproprietary Name; developmental code name IRL752 or IRL-752) is a drug which is under development for the prevention of falls in people with Parkinson's disease and Parkinson's disease dementia. It has been referred to as a "nootrope" (i.e., nootropic or cognitive enhancer).
=== Leaves === The leaves are generally simple, elongated, entire (smooth and even), linear, oval to filiform (threadlike), mostly with parallel veins, but occasionally net-veined. They are alternate (single and alternating direction) and spiral, but may be whorled (three or more attached at one node, e.g. Lilium, Fritillaria), cauline (arranged along the aerial stem) or sheathed in a basal rosette. They are rarely petiolate (stalked), and lack stipules. The aerial stem is unbranched.
Alix Spiegel (2013-12-27). "When Memories Never Fade, The Past Can Poison The Present". NPR. Claire Nowak (2021-06-21). "Only 60 People in the World Have This Insanely Powerful Memory". Reader's Digest. Klochan, Yuliya (2022-05-13). "Understanding the Basis of Superior Memory". Discover Magazine. Jennie Runevitch (2019-02-27). "Total Recall: An IU grad's rare ability creates a map to almost every day of her life". WTHR. Extraordinary Variations of the Human Mind: James McGaugh: Highly Superior Autobiographical Memory. University of California Television (UCTV). 2017-07-12 – via YouTube. People who remember every second of their life. 60 Minutes Australia. 2018-09-21 – via YouTube. Endless Memory, Part 1. CBS News. 2010-12-19 – via YouTube. [Endless Memory, Part 1. CBS News. 2011-06-19 – via YouTube.] Endless Memory, Part 2. CBS News. 2010-12-19 – via YouTube. [Endless Memory, Part 2. CBS News. 2011-06-19 – via YouTube.] Extra: Marilu Henner & "Time Traveling". CBS News. 2010-12-19 – via YouTube. [Extra: Marilu Henner & "time traveling". CBS. 2010-12-19 – via YouTube.] Extra: Memory quiz time. CBS News. 2010-12-19 – via YouTube. [Extra: Memory Quiz Time. CBS. 2010-12-19 – via YouTube.] More people have "Highly Superior Autobiographical Memory" than originally thought. CBS Mornings. 2014-01-13 – via YouTube.
Sources: en.wikipedia.org
This is because the fundamental principle of labour law is that employees' unequal bargaining power justifies substitution of rules in property and contract with positive social rights so that people may earn a living to fully participate in a democratic society. The EU's competences generally follow principles codified in the Community Charter of the Fundamental Social Rights of Workers 1989, introduced in the "social chapter" of the Treaty of Maastricht. Initially the UK had opted-out, because of opposition by the Conservative Party, but was acceded to when the Labour Party won the 1997 general election in the Treaty of Amsterdam.
=== Advanced platelet-rich fibrin === Blood-derived growth factors have been used in medicine and oral surgery for more than twenty years with an abundance of scientific data supporting its role in soft and hard tissue regeneration. APRF, introduced by Dr. Joseph Choukroun, represents the fourth improved generation of such technology and has been widely used in the field of dentistry and oral surgery. Advantages of APRF include no risk of rejection or disease transmission (using your own blood) and improved healing (autogenous growth factors, hematopoietic or mesenchymal stem cells).
== Causes == Myositis can arise from various causes, including injury, certain medications, infections, inherited muscle disorders, or autoimmune conditions. In some instances, the origins of myositis remain idiopathic, without a discernible cause.
== Safety == PET scanning is non-invasive, but it does involve exposure to ionizing radiation. For a typical dose (245 MBq) of FDG, one of the most common radiotracers used for PET neuroimaging and cancer patient management, the effective radiation dose is 4.7 mSv. For combined PET–CT scanning, the radiation exposure contributed by the CT scan may be substantial - ranging from around 3–26 mSv (for a 70 kg person, and depending on the coverage and intended use of the scan). The amount of radiation in a typical FDG PET-CT scan is similar to the effective dose of spending one year in the American city of Denver, Colorado (12.4 mSv/year). For comparison, radiation dosage for other medical procedures range from 0.02 mSv for a chest X-ray and 6.5–8 mSv for a CT scan of the chest. Average civil aircrews are exposed to 3 mSv/year, and the IAEA recommend that whole body effective dose for nuclear energy workers is 20 mSv/year (when averaged over 5 years) and does not exceed 50 mSv in a given year.
Sources: en.wikipedia.org
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.
It became prominent during a 2013 Australian sports investigation that examined whether it was a prohibited growth-hormone-related substance. Subsequent interpretations and list updates have varied, so current rules should be checked directly.
Published summaries generally report limited or inconsistent weight-loss effects, and complete trial data are not widely available. The studies were not sufficient to establish it as an effective obesity treatment.
No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.